Handel Vir Biotechnology, Inc. - VIR CFD

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.